Zobrazeno 1 - 10
of 18
pro vyhledávání: '"35"'
Autor:
Sylke Nagel, Aruna Raghavachar, Ludwig Fischer von Weikersthal, Monika Serke, Ernst-Wilhelm Schmidt, Christine Lautenschlaeger, Hans Schweisfurth, Wolfgang Schuette, Ina Dittrich, Klaus Hans, Thomas Blankenburg, Angelika Reißig
Publikováno v:
Journal of Clinical Oncology. 23:8389-8395
Purpose A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule. Patients and Methods Patients with stage IIIB-IV non–small-cell lung cancer (NSCLC) were randomly
Autor:
Matthew A. Williams, Robert B. Livingston, G. K. Ellis, C A Long, R White, C McGuirt, Julie R. Gralow, B B Adamkiewicz
Publikováno v:
Journal of Clinical Oncology. 15:1395-1400
PURPOSE We evaluated weekly single-agent intravenous (IV) vinorelbine as salvage therapy for metastatic breast cancer. After the first five patients, all received elective growth factor support with granulocyte colony-stimulating factor (G-CSF; filgr
Autor:
John C. Ruckdeschel, P. Bonomi, Antonio C. Wolff, Donna Neuberg, David H. Johnson, David S. Ettinger, Robert L. Comis
Publikováno v:
Journal of Clinical Oncology. 13:1615-1622
PURPOSE A phase II study of ifosfamide, carboplatin, and prolonged oral administration of etoposide (ICE) in patients with untreated extensive-disease (ED) small-cell lung cancer (SCLC) was conducted to assess toxicities, response, and median surviva
Autor:
E I Smith, Bennett L. Leventhal, Vijay V. Joshi, Donald H. Mahoney, Robert P. Castleberry, R L Berkow, Alexander A. Green, Alan B. Cantor, George R. Buchanan, F A Hayes
Publikováno v:
Journal of Clinical Oncology. 12:1616-1620
PURPOSE Children less than 1 year of age with metastatic neuroblastoma NB are at high risk of death. The need to identify new and effective chemotherapy agents is clear. A study was conducted by the Pediatric Oncology Group (POG) to determine the eff
Autor:
Richard G. Hahn, Lawrence H. Einhorn, Paul Elson, Richard D. Williams, Patrick J. Loehrer, Robert Dreicer, Craig R. Nichols
Publikováno v:
Journal of Clinical Oncology. 12:483-488
PURPOSE This multicenter cooperative group phase I/II trial evaluated the toxicity and efficacy of escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) with recombinant human granulocyte colony-stimulating factor (rhG-CS
Autor:
T M Waits, Mary L. McMaster, F A Greco, John D. Hainsworth, Richard S. Stein, S. N. Wolff, David H. Johnson, John P. Greer
Publikováno v:
Journal of Clinical Oncology. 11:943-949
PURPOSE Despite substantial advances in the treatment of aggressive non-Hodgkin's lymphoma, therapeutic results with conventional regimens remain poor in some subsets of patients. In an attempt to improve the prognosis of such patients we used an 8-w
Autor:
Charles R. Fitz, Minesh P. Mehta, Joanne M. Hilden, Tianni Zhou, Nancy J. Tarbell, Joel W. Goldwein, Arzu Onar, Roger J. Packer, Regina I. Jakacki, Emiko J. Holmes, Peter C. Burger, Ian F. Pollack, Mehmet Kocak, Gilbert Vezina
Publikováno v:
Journal of Clinical Oncology. 30:2648-2653
Purpose We evaluated the feasibility of administering carboplatin as a radiosensitizer during craniospinal radiation therapy (CSRT) to patients with high-risk medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumors, and we report t
Autor:
Moacyr Ribeiro de Oliveira, D. Ross Camidge, Elizabeth Litvinovich, Yi-Lin Chiu, Cathy E. Nolan, Charles M. Rudin, Divis Khaira, Geoffrey I. Shapiro, Todd A. Busman, Hao Xiong, Caroline Dive, David R. Gandara, Evelyn McKeegan, Philip Bonomi, Sari H. Enschede, Rod A. Humerickhouse, Andrew Krivoshik, Leena Gandhi, Philip M. Hemken, Christine L. Hann
Publikováno v:
Journal of Clinical Oncology. 29:909-916
Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel in
Autor:
Ana Lluch, Monica Fornier, David Lebwohl, Edgardo Rivera, Linda T. Vahdat, Patrice Viens, José Baselga, Eva Thomas, Valentina Guarneri, Valerie Poulart, Josep Tabernero, J. Klimovsky, Pierfranco Conte, Howard A. Burris, Miguel Martin, Craig A. Bunnell, Pierre Fumoleau
Publikováno v:
Journal of Clinical Oncology. 25:3399-3406
Purpose Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring epothilone B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin and stabilizing microtubules, causing apo
Autor:
Judith G, Villablanca, Mark D, Krailo, Matthew M, Ames, Joel M, Reid, Gregory H, Reaman, C Patrick, Reynolds, Patrick C, Reynolds
Publikováno v:
Journal of Clinical Oncology. 24:3423-3430
PurposeTo determine the maximal tolerated dosage (MTD) of oral fenretinide given as intact capsules for 7 days, repeated every 21 days, in children with high-risk solid tumors.MethodsChildren 21 years of age or younger received daily doses from 350 m